JP2024519964A5 - - Google Patents

Info

Publication number
JP2024519964A5
JP2024519964A5 JP2023572168A JP2023572168A JP2024519964A5 JP 2024519964 A5 JP2024519964 A5 JP 2024519964A5 JP 2023572168 A JP2023572168 A JP 2023572168A JP 2023572168 A JP2023572168 A JP 2023572168A JP 2024519964 A5 JP2024519964 A5 JP 2024519964A5
Authority
JP
Japan
Prior art keywords
administered
day
multispecific protein
cancer
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030323 external-priority patent/WO2022246244A1/en
Publication of JP2024519964A publication Critical patent/JP2024519964A/ja
Publication of JP2024519964A5 publication Critical patent/JP2024519964A5/ja
Pending legal-status Critical Current

Links

JP2023572168A 2021-05-21 2022-05-20 タンパク質治療薬のための投薬レジメン Pending JP2024519964A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163191488P 2021-05-21 2021-05-21
US63/191,488 2021-05-21
US202163253714P 2021-10-08 2021-10-08
US63/253,714 2021-10-08
PCT/US2022/030323 WO2022246244A1 (en) 2021-05-21 2022-05-20 Dosing regimens for protein therapeutics

Publications (2)

Publication Number Publication Date
JP2024519964A JP2024519964A (ja) 2024-05-21
JP2024519964A5 true JP2024519964A5 (cg-RX-API-DMAC10.html) 2025-05-27

Family

ID=82258425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572168A Pending JP2024519964A (ja) 2021-05-21 2022-05-20 タンパク質治療薬のための投薬レジメン

Country Status (7)

Country Link
US (1) US20240262920A1 (cg-RX-API-DMAC10.html)
EP (1) EP4341291A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024519964A (cg-RX-API-DMAC10.html)
KR (1) KR20240024819A (cg-RX-API-DMAC10.html)
AU (1) AU2022276523A1 (cg-RX-API-DMAC10.html)
CA (1) CA3219832A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022246244A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149821A1 (en) * 2023-01-13 2024-07-18 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
WO2025181039A1 (en) * 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
KR20110044991A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TNF-α 길항제 다-표적 결합 단백질
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
IN2014MN02293A (cg-RX-API-DMAC10.html) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
EP3515491A4 (en) * 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
EP3953391A1 (en) * 2019-04-10 2022-02-16 MacroGenics, Inc. Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies

Similar Documents

Publication Publication Date Title
KR102009238B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
JP2025111463A5 (cg-RX-API-DMAC10.html)
KR101968498B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
JP2021510736A5 (cg-RX-API-DMAC10.html)
JP2021514664A5 (cg-RX-API-DMAC10.html)
JP2025000862A5 (cg-RX-API-DMAC10.html)
JP2021524244A5 (cg-RX-API-DMAC10.html)
Zhang et al. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy
JP2025506318A5 (cg-RX-API-DMAC10.html)
JP2023546743A5 (cg-RX-API-DMAC10.html)
JP2022526420A5 (cg-RX-API-DMAC10.html)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2021528047A5 (cg-RX-API-DMAC10.html)
JP2025038088A5 (cg-RX-API-DMAC10.html)
IL297619A (en) Use of a multimeric anti-dr5 binding compound in combination with cancer therapy for the treatment of cancer
JP2022543780A5 (cg-RX-API-DMAC10.html)
EP2683737A1 (en) Extracellular targeted drug conjugates
US20250270323A1 (en) Hhla2 binding agents with novel activity
EP4640707A1 (en) Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof
JP2024515879A5 (cg-RX-API-DMAC10.html)
US20210023211A1 (en) Combination of anti-fgfr4-antibody and bile acid sequestrant
JP2025516590A5 (cg-RX-API-DMAC10.html)
JP2024522075A5 (cg-RX-API-DMAC10.html)
JP2024519078A5 (cg-RX-API-DMAC10.html)
JP2023500409A5 (cg-RX-API-DMAC10.html)